PerkinElmer Further Expands Industry-Leading Signals™ Informatics Capabilities in Biologics Drug Discovery
17.3.2021 19:03:00 EET | Business Wire | Press release
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its industry-leading documentation, workflow and decision making Signals™ informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with Insightful Science, a software company serving the global life sciences community.
With the collaboration, pharmaceutical and academic research teams can bring together the power of the PerkinElmer Signals™ platform with leading solutions from Insightful Science’s Bioinformatics division. This includes the popular SnapGene and Geneious Prime software offerings that help molecular biologists design and execute DNA construct design, molecular cloning and other kinds of molecular biology research. The integration will give scientists the ability to access and compare data across experiments and instruments and collaborate more intuitively. They can also replicate assays and experiments instantly, leading to faster time-to-result and more informed decision making on drug and vaccine targets.
“There is a limited availability of IT tools in the biologics space,” said Kevin Willoe, VP and GM of PerkinElmer, Informatics. “Through our collaboration with Insightful Science, we’re able to provide enhanced informatics capabilities to scientists doing vital biologics and vaccine research. This will help significantly reduce cycle times for researchers and aid them in making data-driven decisions faster and more accurately - important capabilities when fighting foes like cancer, cardio, neurological and viral diseases.”
"The integration of best-in-class scientific software with cloud-based data platforms is increasingly essential for modern pharmaceutical and biotech enterprises to streamline research and ensure the integrity of valuable data,” added Brett Ammundsen, CEO Bioinformatics at Insightful Science. “The combination of SnapGene and Geneious Prime software with the PerkinElmer Signals platform powerfully enhances research workflows and enriches collaboration. Ultimately this will better connect scientists to their ideas and data, so they can focus on producing life-changing outcomes.”
For more information about the PerkinElmer Signals™ platform, click here. To learn more about Insightful Science, including the Geneious Prime and SnapGene software offerings, visit www.insightfulscience.com.
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
About Insightful Science
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data, advancing the discovery process. From developing new personalized and preventive patient treatment solutions to reversing climate change — more than 2 million researchers at leading life science and biopharma enterprises trust Insightful Science products to make the world a healthier, cleaner, and better place to live. Products within the Insightful Science portfolio were built by prominent scientists, and include GraphPad Prism, Geneious Prime and Geneious Biologics, SnapGene, nQuery, Cytapex, and more. Visit www.insightfulscience.com for more information about the company and its products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005650/en/
Contact information
PerkinElmer Media Relations:
Adriana Howell
765-918-3070
adriana.howell@perkinelmer.com
Insightful Science Media Relations
media@insightfulscience.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Board Chair Michael Moritz Acquires 3.47 Million Shares for $50 Million13.3.2026 12:05:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today discloses the following transactions by the Chair of its Board of Directors and Chief Product & Design Officer, filed with the U.S. Securities and Exchange Commission on Form 3. Share Purchases Michael Moritz, Chairman, through an associated entity, purchased 3,472,845 ordinary shares between March 3 and March 11, 2026, at an aggregate consideration of $49,913,138.73. David Fock, Chief Product & Design Officer, purchased 27,000 ordinary shares on March 9, 2026, for an aggregate consideration of $388,552.14. Share Sales David Sandström, Chief Marketing Officer, sold 32,703 shares on March 9, 2026, pursuant to a Rule 10b5-1 trading plan, established in 2025. David Sykes, Chief Commercial Officer, sold 23,799 shares on March 13, 2026, pursuant to a separately established Rule 10b5-1 trading plan, established in 2025. Form 3 filings for all transactions are available on the SEC's EDGAR database atwww.sec.gov. Forward-Looking Statements This press release
Intertek Launches Comprehensive Digital Product Passport Services13.3.2026 11:00:00 EET | Press release
Intertek, a leading Total Quality Assurance provider to industries worldwide, has announced the launch of its enhanced Digital Product Passport (DPP) suite of services. This includes a comprehensive advisory service designed to help manufacturers, brands and retailers navigate the fast-evolving regulatory and sustainability landscape associated with digital product passports and circular economy compliance. Mark Thomas, Executive Vice President, Global Sustainability, Assurance, Agri World and Food at Intertek, said: “With the introduction of regulatory frameworks for improving the sustainability performance of products, companies are facing mounting pressure to implement robust systems for transparency, traceability and sustainability reporting globally. This shift marks a significant regulatory milestone, requiring organisations to strengthen data governance, engage suppliers more effectively and demonstrate credible, verifiable sustainability performance across the full product life
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 22:50:00 EET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 16:38:00 EET | Press release
Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net profit was at €250.9 million. In 2024, the corresponding value was €211.1 million. Following the results achieved in 2025, the Reply Board of Directors decided to propose to the next Shareholders’ Meeting a dividend distribution of €1.35 per share, which will be payable on 20 May 2026, with dividend date set on 18 May 2026 (record
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 15:51:00 EET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom